151751-Najiba-Chargi

240 CHAPTER 13 include sufficient data to calculate odds ratios (n = 6), 22,26,32,37,39,41 did not dichotomize low SMM (n = 4), 28,29,34,36 or featured a toxicity endpoint that did not match with any other studies (n = 2). 6,38 Figure 1. Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) flowchart de - tailing the study selection process. STUDY CHARACTERISTICS Table 1 shows the characteristics of the included studies. Samples sizes ranged from 21 to 414 patients with a total sample size of 2918 patients. The study populations existed of patients with a variety of cancer types. The most frequent were esophageal, renal, colorectal, breast, and head and neck cancer. The occurrence of low SMM ranged from 12.2% to 89.0%. The endpoint used to measure toxicity varied between studies. Most studies used DLT, defined as toxicity leading to dose reduction, treatment delay, or treatment discontinuation. Another commonmeasurement of toxicity was according to the CTCAE grading system. The occurrence of toxicity ranged from21.8% to 77.4%. Supplementary Table S1 shows additional information regarding the treatment specificities of the included studies, such as treatment intent, primary or adjuvant treatment, and the addition of radiotherapy.